問卷

TPIDB > Study Site

Study Site



Taipei Veterans General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

篩選

List

2245Cases

2016-12-13 - 2017-10-30

Phase III

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) in Healthy Subjects Aged 3 Years Old to 17 Years Old
  • Condition/Disease

    Influenza

  • Test Drug

    Quadrivalent inactivated split (QIS) influenza vaccine (AdimFlu-S (QIS)

Participate Sites
2Sites

Terminated2Sites

2015-12-10 - 2019-12-31

IIT

Phase II

A PHASE II, OPEN LABEL, MULTICENTER STUDY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB VERSUS ERLOTINIB ALONE IN PATIENTS WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES.
  • Condition/Disease

    NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES

  • Test Drug

    (1)Avastin; (2) Erlotinib

Participate Sites
3Sites

Recruiting3Sites

2013-08-01 - 2015-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-02-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-07-01 - 2012-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-03-01 - 2021-10-13

Phase III

An Open-Label, Randomized, Parallel-Group, Multi-Site Study to Evaluate the Efficacy and Safety of Azelastine HCl-Fluticasone propionate Nasal Spray 137-50 mcg/spray in Perennial Allergic Rhinitis patients
  • Condition/Disease

    Perennial Allergic Rhinitis

  • Test Drug

    Azelastine HCl及Fluticasone propionate 137/50

Participate Sites
5Sites

Recruiting5Sites

2018-07-31 - 2020-01-31

Phase III

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Imidafenacin in Patients with Overactive Bladder
  • Condition/Disease

    Overactive Bladder

  • Test Drug

    Uritos

Participate Sites
12Sites

Terminated11Sites

2008-04-01 - 2008-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-08-01 - 2017-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-05-01 - 2017-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites